As expected, Germany's Schwarz Pharma won FDA approval to market its Neupro patch for Parkinson's disease. "Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease," said the FDA in a statement. The patch delivers the therapy rotigotine for the brain disease. Rotigotine is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning. The system is applied to the skin once a day and provides rotigotine continuously to the body for 24 hours.
- check out the release for more information